We expect the ulcerative colitis (UC) market to grow steadily over the next decade. The availability of non-TNF biologics (e.g., Takeda’s Entyvio, Janssen’s Stelara) and the first oral JAK inhibitor (Pfizer’s Xeljanz / Xeljanz XR) have expanded physicians’ treatment armamentarium and intensified market competition. Additionally, the recent approvals of BMS’s Zeposia and Gilead / Galapagos’s Jyseleca and the expected launch of several emerging therapies with novel MOAs will drive market growth over the next decade. In balance with these factors, the continued generic erosion of conventional agents and the entry of and increased physician comfort with less expensive biosimilars will constrain the UC market and create hurdles that emerging therapies will need to overcome to secure uptake.
Geographies: United States, EU5, Japan.
Primary research: 34 country-specific interviews with thought-leading gastroenterologists supported by survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed prevalence of UC by country, segmented by disease activity.
Forecast: Ten-year, annualized, drug-level sales and patient share of key UC therapies through 2030, segmented by brands / generics / biosimilars, and acute and maintenance settings.
Emerging therapies: Phase III/PR: ~9 drugs; coverage of select early-phase products.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast will feature continuous updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.